Spots Global Cancer Trial Database for Cardiac Toxicity in Medical Treatment of Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Cardiac Toxicity in Medical Treatment of Breast Cancer
Official Title: Cardiac Toxicity in Medical Treatment of Breast Cancer
Study ID: NCT02440620
Interventions
Study Description
Brief Summary: This study will describe the epidemiology including prognosis of heart failure related to treatment with anthracycline and trastuzumab for breast cancer. In a prospective study Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer patients scheduled for trastuzumab treatment at Odense University Hospital, will be offered advanced echocardiographic examination, test of bio-markers and genetic markers for the purpose of investigating if early identification of patients in particular risk of developing heart failure is feasible.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Odense University Hospital, Odense c, , Denmark
Contact Details
Name: Jacob Moeller, MD, DMsc
Affiliation: Odense University Hospital
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
